Cargando…

Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases

INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Papagoras, Charalampos, Zioga, Nikoleta, Papadopoulos, Vasileios, Gerolymatou, Nafsika, Kalavri, Eleni, Bounos, Christos, Simopoulou, Theodora, Fragoulis, George E., Panopoulos, Stylianos, Fragiadaki, Kalliopi, Evangelatos, Gerasimos, Bournia, Vasiliki-Kalliopi, Arida, Aikaterini, Karamanakos, Anastasios, Pappa, Maria, Kravvariti, Evrydiki, Deftereou, Kleopatra, Kougkas, Nikolaos, Zampeli, Evangelia, Kataxaki, Evangelia, Melissaropoulos, Konstantinos, Barouta, Georgia, Panagiotopoulos, Alexandros, Koutsianas, Christos, Liossis, Stamatis-Nick, Georgiou, Panagiotis, Dimitroulas, Theodoros, Tektonidou, Maria G., Bogdanos, Dimitrios P., Elezoglou, Antonia, Voulgari, Paraskevi V., Sfikakis, Petros P., Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640401/
https://www.ncbi.nlm.nih.gov/pubmed/37731083
http://dx.doi.org/10.1007/s10067-023-06769-4
_version_ 1785146623695781888
author Papagoras, Charalampos
Zioga, Nikoleta
Papadopoulos, Vasileios
Gerolymatou, Nafsika
Kalavri, Eleni
Bounos, Christos
Simopoulou, Theodora
Fragoulis, George E.
Panopoulos, Stylianos
Fragiadaki, Kalliopi
Evangelatos, Gerasimos
Bournia, Vasiliki-Kalliopi
Arida, Aikaterini
Karamanakos, Anastasios
Pappa, Maria
Kravvariti, Evrydiki
Deftereou, Kleopatra
Kougkas, Nikolaos
Zampeli, Evangelia
Kataxaki, Evangelia
Melissaropoulos, Konstantinos
Barouta, Georgia
Panagiotopoulos, Alexandros
Koutsianas, Christos
Liossis, Stamatis-Nick
Georgiou, Panagiotis
Dimitroulas, Theodoros
Tektonidou, Maria G.
Bogdanos, Dimitrios P.
Elezoglou, Antonia
Voulgari, Paraskevi V.
Sfikakis, Petros P.
Vassilopoulos, Dimitrios
author_facet Papagoras, Charalampos
Zioga, Nikoleta
Papadopoulos, Vasileios
Gerolymatou, Nafsika
Kalavri, Eleni
Bounos, Christos
Simopoulou, Theodora
Fragoulis, George E.
Panopoulos, Stylianos
Fragiadaki, Kalliopi
Evangelatos, Gerasimos
Bournia, Vasiliki-Kalliopi
Arida, Aikaterini
Karamanakos, Anastasios
Pappa, Maria
Kravvariti, Evrydiki
Deftereou, Kleopatra
Kougkas, Nikolaos
Zampeli, Evangelia
Kataxaki, Evangelia
Melissaropoulos, Konstantinos
Barouta, Georgia
Panagiotopoulos, Alexandros
Koutsianas, Christos
Liossis, Stamatis-Nick
Georgiou, Panagiotis
Dimitroulas, Theodoros
Tektonidou, Maria G.
Bogdanos, Dimitrios P.
Elezoglou, Antonia
Voulgari, Paraskevi V.
Sfikakis, Petros P.
Vassilopoulos, Dimitrios
author_sort Papagoras, Charalampos
collection PubMed
description INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan–Meier curves were used to depict survival data. RESULTS: From August 2020 until June 30, 2022, 456 cases (70.2% females) of COVID-19 with a mean age (± SD) of 51.4 ± 14.0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24.5% and 4%, compared to 12.5% and 0.8% in the vaccinated group (p < 0.001 for both comparisons). The rates of hospitalization for the wild-type, Alpha, Delta, and Omicron periods were 24.7%, 31.3%, 25.9%, and 8.1% respectively (p < 0.0001), while the case fatality rates were 2.7%, 4%, 7%, and 0%, respectively (p = 0.001). Using multivariable regression analysis, factors independently associated with hospitalization were infection by a non-Omicron variant, being non-vaccinated, exposure to rituximab, older age, and respiratory and cardiovascular disease. Independent predictors for death were contracting COVID-19 during the Alpha or Delta period, pulmonary disease, and older age, while being vaccinated was protective. CONCLUSIONS: In this 2-year analysis, the rates of hospitalization and death among patients with SAIRDs have declined significantly. Vaccination and the dominance of the Omicron variant appear to be the major determinants for this shift. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-023-06769-4.
format Online
Article
Text
id pubmed-10640401
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106404012023-11-14 Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases Papagoras, Charalampos Zioga, Nikoleta Papadopoulos, Vasileios Gerolymatou, Nafsika Kalavri, Eleni Bounos, Christos Simopoulou, Theodora Fragoulis, George E. Panopoulos, Stylianos Fragiadaki, Kalliopi Evangelatos, Gerasimos Bournia, Vasiliki-Kalliopi Arida, Aikaterini Karamanakos, Anastasios Pappa, Maria Kravvariti, Evrydiki Deftereou, Kleopatra Kougkas, Nikolaos Zampeli, Evangelia Kataxaki, Evangelia Melissaropoulos, Konstantinos Barouta, Georgia Panagiotopoulos, Alexandros Koutsianas, Christos Liossis, Stamatis-Nick Georgiou, Panagiotis Dimitroulas, Theodoros Tektonidou, Maria G. Bogdanos, Dimitrios P. Elezoglou, Antonia Voulgari, Paraskevi V. Sfikakis, Petros P. Vassilopoulos, Dimitrios Clin Rheumatol Original Article INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan–Meier curves were used to depict survival data. RESULTS: From August 2020 until June 30, 2022, 456 cases (70.2% females) of COVID-19 with a mean age (± SD) of 51.4 ± 14.0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24.5% and 4%, compared to 12.5% and 0.8% in the vaccinated group (p < 0.001 for both comparisons). The rates of hospitalization for the wild-type, Alpha, Delta, and Omicron periods were 24.7%, 31.3%, 25.9%, and 8.1% respectively (p < 0.0001), while the case fatality rates were 2.7%, 4%, 7%, and 0%, respectively (p = 0.001). Using multivariable regression analysis, factors independently associated with hospitalization were infection by a non-Omicron variant, being non-vaccinated, exposure to rituximab, older age, and respiratory and cardiovascular disease. Independent predictors for death were contracting COVID-19 during the Alpha or Delta period, pulmonary disease, and older age, while being vaccinated was protective. CONCLUSIONS: In this 2-year analysis, the rates of hospitalization and death among patients with SAIRDs have declined significantly. Vaccination and the dominance of the Omicron variant appear to be the major determinants for this shift. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-023-06769-4. Springer International Publishing 2023-09-21 2023 /pmc/articles/PMC10640401/ /pubmed/37731083 http://dx.doi.org/10.1007/s10067-023-06769-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Papagoras, Charalampos
Zioga, Nikoleta
Papadopoulos, Vasileios
Gerolymatou, Nafsika
Kalavri, Eleni
Bounos, Christos
Simopoulou, Theodora
Fragoulis, George E.
Panopoulos, Stylianos
Fragiadaki, Kalliopi
Evangelatos, Gerasimos
Bournia, Vasiliki-Kalliopi
Arida, Aikaterini
Karamanakos, Anastasios
Pappa, Maria
Kravvariti, Evrydiki
Deftereou, Kleopatra
Kougkas, Nikolaos
Zampeli, Evangelia
Kataxaki, Evangelia
Melissaropoulos, Konstantinos
Barouta, Georgia
Panagiotopoulos, Alexandros
Koutsianas, Christos
Liossis, Stamatis-Nick
Georgiou, Panagiotis
Dimitroulas, Theodoros
Tektonidou, Maria G.
Bogdanos, Dimitrios P.
Elezoglou, Antonia
Voulgari, Paraskevi V.
Sfikakis, Petros P.
Vassilopoulos, Dimitrios
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title_full Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title_fullStr Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title_full_unstemmed Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title_short Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
title_sort omicron variant dominance and anti-sars-cov-2 vaccination are key determinants for a milder course of covid-19 in patients with systemic autoimmune rheumatic diseases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640401/
https://www.ncbi.nlm.nih.gov/pubmed/37731083
http://dx.doi.org/10.1007/s10067-023-06769-4
work_keys_str_mv AT papagorascharalampos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT zioganikoleta omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT papadopoulosvasileios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT gerolymatounafsika omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT kalavrieleni omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT bounoschristos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT simopouloutheodora omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT fragoulisgeorgee omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT panopoulosstylianos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT fragiadakikalliopi omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT evangelatosgerasimos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT bourniavasilikikalliopi omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT aridaaikaterini omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT karamanakosanastasios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT pappamaria omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT kravvaritievrydiki omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT deftereoukleopatra omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT kougkasnikolaos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT zampelievangelia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT kataxakievangelia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT melissaropouloskonstantinos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT baroutageorgia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT panagiotopoulosalexandros omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT koutsianaschristos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT liossisstamatisnick omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT georgioupanagiotis omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT dimitroulastheodoros omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT tektonidoumariag omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT bogdanosdimitriosp omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT elezoglouantonia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT voulgariparaskeviv omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT sfikakispetrosp omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases
AT vassilopoulosdimitrios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases